{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T20:36:42Z","timestamp":1774903002183,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.vaccine.2024.04.084","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T12:03:55Z","timestamp":1715342635000},"page":"3699-3709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Vu","family":"Dinh Thiem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pham Thi","family":"Van Anh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu","family":"Van Men","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Thai","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-719X","authenticated-orcid":false,"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akari","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6176-8651","authenticated-orcid":false,"given":"Hidenori","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8235-1954","authenticated-orcid":false,"given":"Yuka","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.04.084_b0005","unstructured":"Aleem A, Akbar Samad AB, Vaqar S. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19) [Updated May 8, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 January. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570580\/."},{"key":"10.1016\/j.vaccine.2024.04.084_b0010","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard; 2023. https:\/\/covid19.who.int\/. Accessed July 12, 2023."},{"key":"10.1016\/j.vaccine.2024.04.084_b0015","unstructured":"World Heath Organization. WHO coronavirus (COVID-19) dashboard Viet Nam situation; 2023. https:\/\/covid19.who.int\/region\/wpro\/country\/vn. Accessed July 18, 2023."},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.084_b0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.084_b0025","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2024.04.084_b0030","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape; 2023. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed July 19, 2023."},{"key":"10.1016\/j.vaccine.2024.04.084_b0035","unstructured":"World Health Organization. COVID-19 vaccines with WHO emergency use listing; 2023. https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued. Accessed July 19, 2023."},{"key":"10.1016\/j.vaccine.2024.04.084_b0040","unstructured":"COVID19 vaccine tracker. 11 Vaccines granted emergency use listing (EUL) by WHO; 2023. https:\/\/covid19.trackvaccines.org\/agency\/who\/. Accessed July 19, 2023."},{"key":"10.1016\/j.vaccine.2024.04.084_b0045","unstructured":"COVID19 vaccine tracker. 8 Vaccines approved for use in Viet Nam; 2023. https:\/\/covid19.trackvaccines.org\/country\/viet-nam\/. Accessed July 19, 2023."},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.084_b0050","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines","volume":"54","author":"Fernandes","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.vaccine.2024.04.084_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.997635","article-title":"The COVID-19 endemic in Vietnam: contextual considerations and implications","volume":"11","author":"Doan","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2024.04.084_b0060","unstructured":"World Health Organization. Statement on the update of WHO\u2019s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest; 2023. https:\/\/www.who.int\/news\/item\/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest. Accessed July 26, 2023."},{"key":"10.1016\/j.vaccine.2024.04.084_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.834098","article-title":"SARS-CoV-2\u2019s variants of concern: a brief characterization","volume":"13","author":"Scovino","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.04.084_b0070","unstructured":"CoVariants. Overview of variants in Vietnam; 2023. https:\/\/covariants.org\/per-country?country=Vietnam. Accessed July 20, 2023."},{"issue":"31","key":"10.1016\/j.vaccine.2024.04.084_b0075","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2022.05.081","article-title":"Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys","volume":"40","author":"Hashimoto","year":"2022","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2024.04.084_b0080","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/j.vaccine.2022.04.054","article-title":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: a report of interim findings","volume":"40","author":"Iwata","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2024.04.084_b0085","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.vaccine.2022.12.025","article-title":"Results from a preclinical study in rodents and a Phase 1\/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults","volume":"41","author":"Sonoyama","year":"2023","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2024.04.084_b0090","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1016\/j.vaccine.2022.06.032","article-title":"Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2\/3, randomized, observer-blinded, noninferiority study","volume":"40","author":"Shinkai","year":"2022","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.084_b0095","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/biot.201400438","article-title":"The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors","volume":"10","author":"Felberbaum","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2024.04.084_b0100","unstructured":"Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR [published correction appears in Euro Surveill. 2020 Apr;25(14):] [published correction appears in Euro Surveill. 2020 Jul;25(30):] [published correction appears in Euro Surveill. 2021 Feb;26(5):]. Euro Surveill 2020;25(3):2000045."},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.084_b0105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"282","key":"10.1016\/j.vaccine.2024.04.084_b0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.084_b0115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2024.04.084_b0120","unstructured":"VIEW-hub. Results of COVID-19 vaccine effectiveness studies: an ongoing systematic review; Updated May 12, 2022. https:\/\/view-hub.org\/sites\/default\/files\/2022-06\/COVID19%20VE%20Studies_Forest%20Plots_Delta_Omicron_01Jun2022_Archived.pdf. Accessed July 20, 2023."},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.084_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.084_b0130","unstructured":"UK Health Security Agency. COVID-19 vaccine surveillance reports (Week 48). December 1, 2022. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1134074\/vaccine-surveillance-report-week-48-2022.pdf. Accessed July 20, 2023."},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.084_b0135","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.04.084_b0140","doi-asserted-by":"crossref","unstructured":"Lau JJ, Cheng SMS, Leung K, et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population [published correction appears in Nat Med. 2024 Jan;30(1):305]. Nat Med 2023;29(2):348\u201357.","DOI":"10.1038\/s41591-023-02648-2"},{"issue":"16","key":"10.1016\/j.vaccine.2024.04.084_b0145","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.084_b0150","unstructured":"Voysey M, Clemens SAC, Madhi SA, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111. Erratum in: Lancet 2021;397(10269):98."},{"key":"10.1016\/j.vaccine.2024.04.084_b0155","unstructured":"Iwata S, Pollard AJ, Tada Y, et al. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOxl nCoV-19 in Japanese adults. Sci Rep [in press]."},{"key":"10.1016\/j.vaccine.2024.04.084_b0160","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"18","key":"10.1016\/j.vaccine.2024.04.084_b0165","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24005231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24005231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T10:43:34Z","timestamp":1720867414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24005231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0264410X24005231"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}